165 related articles for article (PubMed ID: 21830747)
1. 16-Gy low-voltage x-ray irradiation with ranibizumab therapy for AMD: 6-month safety and functional outcomes.
Canton VM; Quiroz-Mercado H; Velez-Montoya R; Lopez-Miranda MJ; Moshfeghi AA; Shusterman EM; Kaiser PK; Sanislo SR; Gertner M; Moshfeghi DM
Ophthalmic Surg Lasers Imaging; 2011; 42(6):468-73. PubMed ID: 21830747
[TBL] [Abstract][Full Text] [Related]
2. 24-Gy low-voltage x-ray irradiation with ranibizumab therapy for neovascular AMD: 6-month safety and functional outcomes.
Canton VM; Quiroz-Mercado H; Velez-Montoya R; Lopez-Miranda MJ; Moshfeghi AA; Shusterman EM; Kaiser PK; Sanislo SR; Gertner M; Moshfeghi DM
Ophthalmic Surg Lasers Imaging; 2012; 43(1):20-4. PubMed ID: 22251841
[TBL] [Abstract][Full Text] [Related]
3. 16-Gy low-voltage x-ray irradiation followed by as-needed ranibizumab therapy for AMD: 6-month outcomes of a "radiation-first" strategy.
Moshfeghi AA; Canton VM; Quiroz-Mercado H; Velez-Montoya R; Lopez-Miranda MJ; Shusterman EM; Kaiser PK; Sanislo SR; Gertner M; Moshfeghi DM
Ophthalmic Surg Lasers Imaging; 2011; 42(6):460-7. PubMed ID: 21830745
[TBL] [Abstract][Full Text] [Related]
4. 16 and 24 Gy low-voltage X-ray irradiation with ranibizumab therapy for neovascular age-related macular degeneration: 12-month outcomes.
Morales-Canton V; Quiroz-Mercado H; Velez-Montoya R; Zavala-Ayala A; Moshfeghi AA; Shusterman EM; Kaiser PK; Sanislo SR; Gertner M; Moshfeghi DM
Am J Ophthalmol; 2013 Jun; 155(6):1000-1008.e2. PubMed ID: 23497847
[TBL] [Abstract][Full Text] [Related]
5. 16 Gy low-voltage x-ray irradiation followed by as needed ranibizumab therapy for age-related macular degeneration: 12 month outcomes of a 'radiation-first' strategy.
Moshfeghi AA; Morales-Canton V; Quiroz-Mercado H; Velez-Montoya R; Zavala-Ayala A; Shusterman EM; Kaiser PK; Sanislo SR; Gertner M; Moshfeghi DM
Br J Ophthalmol; 2012 Oct; 96(10):1320-4. PubMed ID: 22895887
[TBL] [Abstract][Full Text] [Related]
6. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Brown DM; Chen E; Mariani A; Major JC;
Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
[TBL] [Abstract][Full Text] [Related]
7. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
[TBL] [Abstract][Full Text] [Related]
8. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
9. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET).
Dugel PU; Bebchuk JD; Nau J; Reichel E; Singer M; Barak A; Binder S; Jackson TL;
Ophthalmology; 2013 Feb; 120(2):317-27. PubMed ID: 23174399
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
[TBL] [Abstract][Full Text] [Related]
11. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
12. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
Boyer DS; Heier JS; Brown DM; Francom SF; Ianchulev T; Rubio RG
Ophthalmology; 2009 Sep; 116(9):1731-9. PubMed ID: 19643495
[TBL] [Abstract][Full Text] [Related]
13. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
Spielberg L; Leys A
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study.
Jackson TL; Chakravarthy U; Kaiser PK; Slakter JS; Jan E; Bandello F; O'Shaughnessy D; Gertner ME; Danielson L; Moshfeghi DM;
Ophthalmology; 2013 Sep; 120(9):1893-900. PubMed ID: 23490327
[TBL] [Abstract][Full Text] [Related]
15. Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results.
Dugel PU; Petrarca R; Bennett M; Barak A; Weinberger D; Nau J; Jackson TL
Ophthalmology; 2012 Jul; 119(7):1425-31. PubMed ID: 22465819
[TBL] [Abstract][Full Text] [Related]
16. One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections.
Arias L; Roman I; Masuet-Aumatell C; Rubio MJ; Caminal JM; Catala J; Pujol O
Retina; 2011; 31(7):1261-7. PubMed ID: 21499194
[TBL] [Abstract][Full Text] [Related]
17. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography.
Jackson TL; Dugel PU; Bebchuk JD; Smith KR; Petrarca R; Slakter JS; Jaffe GJ; Nau JA;
Ophthalmology; 2013 Aug; 120(8):1597-603. PubMed ID: 23490325
[TBL] [Abstract][Full Text] [Related]
18. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
Heier JS; Antoszyk AN; Pavan PR; Leff SR; Rosenfeld PJ; Ciulla TA; Dreyer RF; Gentile RC; Sy JP; Hantsbarger G; Shams N
Ophthalmology; 2006 Apr; 113(4):633.e1-4. PubMed ID: 16483659
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.
Gupta B; Adewoyin T; Patel SK; Sivaprasad S
Br J Ophthalmol; 2011 Mar; 95(3):386-90. PubMed ID: 20693484
[TBL] [Abstract][Full Text] [Related]
20. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G
Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
